We have studied the binding of von Willebrand factor to extracellular matrices of endothelial cells and to the vessel wall of human umbilical arteries in relation to its function in supporting platelet adhesion. CLB-RAg 201, an MAb against von Willebrand factor, completely inhibits the binding of von Willebrand factor to collagen type I and type III. CLB-RAg 201 does not inhibit the binding of 'SI-von Willebrand factor to extracellular matrices of endothelial cells, to smooth muscle cells, or to the subendothelium. CLB-RAg 201 partly inhibits platelet adhesion to these surfaces, but this directly affects the interaction between von Willebrand factor and platelets and is not due to inhibition of binding of von Willebrand factor to these surfaces.
Introduction
Adherence of blood platelets at the site of vascular injury is a crucial step in the early phase of hemostasis (1) , thrombogenesis (2) , and atherogenesis (3) . At high wall shear rates, platelet adherence is completely dependent on the presence of von Willebrand factor (4, 5) . Experiments with reconstituted blood have shown that von Willebrand factor is the only plasma protein necessary for the adherence of platelets to human artery subendothelium (6) . von Willebrand factor is present in plasma, blood platelets, and the vessel wall. Endothelial cells are able to synthesize von Willebrand factor (7) . Besides secreting it into the medium, they also deposit it in their extracellular matrix (8) . The von Willebrand factor that is present in the subendothelium can support platelet adherence but plasma von Willebrand factor is necessary for optimal adhesion (5) .
The binding of plasma von Willebrand factor precedes the adherence of platelets (6) . Several groups of investigators have demonstrated that von Willebrand factor binds to collagen types I and III (9) (10) (11) (12) (13) (14) , and exposed collagen at the site of vessel injury has been considered to be involved in the binding ofvon Willebrand factor. Recently, Hormia et al. and Wagner et al. (15, 16) have suggested that not collagen but fibronectin may be the binding site of von Willebrand factor.
We have used a panel of MAbs directed against von Willebrand factor to study the structure-function relationships of von Willebrand factor (5, 14, 17) . We have found two MAbs that cause complete inhibition of platelet adherence at high shear rate (17) . This inhibition went together with the inhibition of ristocetin-induced platelet aggregation and inhibition of binding of von Willebrand factor to platelets induced by ristocetin. We also described a second MAb that caused partial inhibition of platelet adhesion and which was found to inhibit the binding of von Willebrand factor to purified collagen (14) . However, this MAb did not inhibit the binding of von Willebrand factor to subendothelium. To investigate this unexpected finding, we have tested other MAbs for their ability to inhibit binding of von Willebrand factor to subendothelium and to extracellular matrices of cultured smooth muscle cells and endothelial cells.
Here we describe that the binding of von Willebrand factor to extracellular matrices is completely inhibited by an MAb antibody to von Willebrand factor, CLB-RAg 38. CLB-RAg 38 also totally inhibits the adhesion of platelets at high shear rate under conditions in which adhesion is dependent only on plasma von Willebrand factor. CLB-RAg 38 does not inhibit the binding of von Willebrand factor to purified collagen. These results suggest that collagen is not the primary binding site for von Willebrand factor in the vessel wall.
Methods
Cell cultures. Human vascular endothelial cells were isolated from umbilical cords according to Jaffe et al. (18) with some minor modifications (19) . The cells were cultured in a medium consisting of RPMI 1640 (Gibco, Paisley, U.K.) and 20% pooled human serum. After confluence, the cells were subcultured (2 X 104 cells/cm2) on gelatincoated glass coverslips. After [5] [6] [7] d, when the cells reached confluence (8-10 X 104 cells/cm2), the cultures were exposed to 0.1 M NH40H for 30 min at room temperature with gentle shaking. The cell layer was completely removed by this procedure, leaving the underlying extracellular matrix intact, homogeneously and firmly attached to the glass (20) . The coverslips were used for experiments on the same day.
von Willebrand Factor Binding to Vessel Wall Smooth muscle cells were isolated by outgrowth of explants from human umbilical arteries according to the method ofRoss (21) . After 4 wk, a confluent layer of cells was observed. They were identified by their typical growth pattern and formation of multilayers in culture (21) . The smooth muscle cells were cultured in the same culture medium and subcultured as described for the etidothelial cells. The extracellular matrix of smooth muscle cells was isolated at the moment that the cells completely covered the glass coverslip, just before multilayers of cells appeared.
For binding studies of '25I-von Willebrand factor to extracellular matrices, the endothelial and smooth muscle cells were inoculated into microtiter plates (Nunc, Roskilde, Denmark) at a density of 8,000 cells/well. After confluence, the extracellular matrix was isolated as described.
Perfusions. Perfusions with steady flow (22) were carried out with an annular perfusion chamber (23) and a rectangular perfusion chamber (24) . The annular perfusion chamber was used for subendothelium and the rectangular perfusion chamber was used for glass cover slips coated with extracellular matrix. Subendothelium was obtained from human umbilical arteries by removing endothelium by exposure to air (6, 22) , then the vessel was washed three successive times with 10 mM Hepes buffer, pH 7.4, that contained 150 mM NaCI.
Blood from normal human donors was anticoagulated with 1:10 vol 110 mM trisodium citrate. This whole blood was used directly for perfusion experiments. Some perfusions were performed with reconstituted blood. In that case, platelets were first isolated, washed by centrifugation as previously described (10), radiolabeled with "'Inoxine (Byk-Mallinckrodt, CIL, Petten, the Netherlands) (10 !Ci/1.5 X I 08 platelets), treated with 10 MM aspirin, and washed as previously described (10) . Before each perfusion, the perfusate was reconstituted by adding washed red cells to the resuspended platelets in plasma or in a human albumin solution (HAS; KRB containing 0.01 M glucose, 2 mM CaCl2, 19 mM citrate, and 4% human albumin (Sigma Chemical Co., St. Louis, MO) (hematocrit, 0.4; platelet count, 1.14 X 108/ml).
In some experiments, the matrices or subendothelium were preincubated for I h at room temperature with MAbs and diluted 1:100 in PBS. As a control, matrices were incubated with PBS containing control ascites in the same dilution. After the coverslip or subendothelium had been washed extensively, it was inserted into the perfusion chamber and rinsed with 25 ml of 10 mM Hepes-buffered saline, pH 7.4. The perfusate (15 ml) was prewarmed for 5 min at 370C. In some experiments, the perfusate was preincubated with MAbs (1:100 dilution) during this 5 min. The perfusate was recirculated through the perfusion chamber for 5 min under a nonpulsatile steady flow at wall shear rates of 1,300 s-' (matrices) or 1,800 s-' (subendothelium). The coverslip was removed, washed with Hepes saline, and fixed with 0.5% glutaraldehyde as previously described (24) .
Evaluation of platelet adherence. After fixation with glutaraldehyde, the coverslips covered with platelets were stained with May-Grunwald-Giemsa, as previously described (24) . Platelet adhesion was expressed as the percentage ofthe surface covered by platelets. This was evaluated by en face light microscopy at X 1,000. The light microscope was interfaced with an image analyzer (Quantimet 720; Imanco, Royston, U.K.). For every coverslip, 30 fields, each consisting of 500,000 image points (0.028 mm2), were selected at random and evaluated.
Platelet adhesion to subendothelium was determined by counting of " In-radioactivity on the artery segments in a gamma counter.
MAbs and Fabfragments. The preparation and characterization of MAbs directed against the human von Willebran4 factor molecule have been described before (17) . The properties of MAbs CLB-RAg 35 1. Abbreviations used in this paper: buffer A, 28.5 mM Na-acetate, 28.5 mM Na-barbital, 116 mM NaCl, 0.1% Tween 20, and 1 mg/ml BSA; FPLC, fast protein liquid chromatography; HAS, human albumin solution.
and CLB-RAg 201 have been extensively published (5, 14, 17) . IgG was purified from ascites as described (17) . Fab fragments were prepared according to the method described in Immunochemistry in Practice (25) . In short, purified monoclonal IgG was dissolved in 2 ml of 0.1 M Na-acetate and -8 mg IgG was digested with 250 ,ug pepsin (Sigma Chemical Co.) for 18 h at 370C. After neutralizing this solution with 300 Ml of2 M Tris buffer, pH 7.4, and its centrifugation, the F(ab)2 fragments were isolated with Sephadex G200 gel chromatography. After the F(ab)2 fragments were concentrated and dialyzed against Tris-buffered saline (pH 7.4), they were reduced with 1 mM DTT for I h at room temperature. Then iodoacetamide (10 mM final concentration) was added to the Fab fragments which were then isolated with Sephadex G-200 chromatography. SDS-PAGE showed the absence of F(ab)2 fragments in the final preparation. In experiments in which ascites was used instead of purified IgG or Fab fragments, the ascites was diluted 1 :100, which corresponds with I 50 Mg/ml IgG for CLBRAg 38, 40 Mg/ml IgG for CLB-RAg 201, and -30 ug/ml for CLBRAg 35.
Isolation and radiolabeling of von Willebrand factor. von Willebrand factor was isolated from fresh cryoprecipitates by agarose gel filtration on Sepharose CL-4B (Pharmacia, Inc., Uppsala, Sweden) as described previously (26). The von Willebrand factor in the void volume fraction was further purified by passing it over a gelatin Sepharose column, Which was equilibrated with 0.005 M Tris-HCl (pH 7.4). von Willebrand factor was precipitated by dialysis against 1.6 M ammonium sulfate, pH 7.0, at 4°C for 18 h, and was stored as ammonium sulfate suspension at 4°C until use. The purified von Willebrand preparation contained no fibronectin and less than 2% fibrinogen.
For radiolabeling, von Willebrand factor was collected from the ammonium sulfate suspension by centrifugation (10,000 g, 4°C, 2 min). The pellet was dissolved in 0.05 M sodium-phosphate buffer, pH 7.0, and dialyzed against this buffer to remove any remaining ammonium sulfate. Radiolabeling with 1251I was performed with the lodo-Gen method (27) Mumby et al. (28) . In short, wells of 96-well microtiter plates were coated overnight with 100 d1 collagen (5 Mg/ml) in 50 mM acetic acid. The microtiter plate was rinsed three times with buffer A (28.5 mM Na-acetate, 28.5 mM Na-barbital, 116 mM NaCl, 0.1% Tween 20, and 1 mg/ml BSA, pH 7.35). 100 Ml plasma or 100 ,ul purified von Willebrand factor (5 Mg/ml) was added to buffer A for 1 h at room temperature. The plate was rinsed as before, and 100 Ml of a 1:2,000 diluted peroxidase-conjugated rabbit anti-human von Willebrand factor (DAKO, Copenhagen, Denmark) was added for 1 h at room temperature. The plate was rinsed as before and incubated for 20 min at room temperature with 8 mg/ml o-phenylenediamine and 0.0 15% H202 in 50 mM citric acid, 100 mM Na2HPO4, pH 5.0. The reaction was stopped with 4 M H2SO4, and absorbance was determined at 450 nm with a titertek Multiscan microtiter plate autoreactor. (Flow Laboratories, Inc., Rockville, MD).
Collagen types I and III were purified as described (28) . Collagen types IV and V were a generous gift of Dr. Houdijk (University Hospital Utrecht, the Netherlands); collagen type VI was a generous gift of Drs. Dziadek and Timpl, (Max Planck Institute, Munich, FRD).
Fibronectin was isolated from normal human plasma by affinity chromatography on gelatin Sepharose, as published (29) .
Binding ofvon Willebrandfactor to extracellular matrices. Binding of '251-von Willebrand factor to extracellular matrices of cells cultured in 96-well microtiter wells was assayed as follows: '251I-von Willebrand factor was diluted to 2 ,ug/ml in buffer A, and 50 Mul ofthis solution was incubated for 2 h at room temperature in the presence or absence of MAbs in the microtiter wells. After washing the wells three times with 66 and 1% Triton X-100) was added, and the matrices were scraped off the bottom of the wells, transferred to plastic tubes, and counted in a gamma counter. Glutaraldehyde-fixed endothelial or smooth muscle cells or wells without cells were used as blanks. The binding to the blanks were all less than 10% of the binding to the matrices.
The binding of '25I-von Willebrand factor to subendothelium was assayed in the perfusion system (14) . Subendothelium was exposed to I Mg/ml '25I-von Willebrand factor (25 nCi/ml) in 4% HAS for 5 min at a shear rate of 1,800 s-'. The amount of von Willebrand factor that was bound to the surface was calculated from the specific radioactivity and the radioactivity on the surface after perfusion. Radioactivity was measured in a gamma counter.
Binding of von Willebrand factor to platelets. Human blood was collected into 1:10 vol of 1 10 mM trisodium citrate, and platelet-rich plasma was obtained by centrifugation (20'C, 10 min, 150 g). Platelets were washed three times by centrifugation as previously described (6) . After the platelets were washed, they were resuspended in Tyrode buffer (140 mM NaCl, 2.7 mM KCI, 0.42 mM NaH2PO4, and 12 mM NaHCO3, pH 7.4), which contained I mM CaC12, 5 mM glucose, and 3.5 mg/ml of human albumin. 251I-von Willebrand factor was diluted to 4 ,g/ml in this Tyrode buffer. 0.25 ml of this solution was mixed with 0.25 ml platelet suspension, which contained 1.5 X 108 platelets. Thrombin (Sigma Chemical Co.) was added to a final concentration of 0.5 U/ml. 0.8 mg ristocetin was first mixed with the '251I-von Willebrand solution. After incubation for 30 min at room temperature, the mixtures were layered on top of 1 ml 20% sucrose solution and then centrifuged (I min, 10,000 g). The pellet was counted in a gamma counter.
To determine the effect of the MAbs to von Willebrand factor, these antibodies were included in the incubation mixture at a final dilution of 1: 100 (ascites).
Tryptic digestion of von Willebrand factor and separation of the fragments. 45 mg von Willebrand factor in 20 ml of 0.05 M Tris-HCI, 0.1 M NaCl, pH 7.4, was incubated for 24 h at 37°C with L(tosylamido 2-phenyl)ethylchloromethylketone-treated trypsin (Worthington, Freehold, NJ) (enzyme to substrate ratio 1:2.2 [mol/mol]). The incubation was finished with a mixture of inhibitors (12.5 mM benzamidine, 12.5 mM E-aminocaproic acid, and soy bean trypsin inhibitor, twofold molar excess). The digest was fractionated using fast protein liquid chromatography (FPLC) Mono-Q ionexchange chromatography (Pharmacia, Inc.). The column was equilibrated with 20 mM Tris-HCI, pH 7.6, and 0.1% Tween 20; under these conditions all peptides bound to the column. The tryptic fragments were eluted with a linear gradient of NaCl (0-0.5 M), and fractions were collected. The absorbance at 280 nM of the eluate was recorded continuously with a spectrophotometer (Uvicord S; LKB Instruments, Bromma, Sweden). Peak fractions were pooled as indicated and applied to gel electrophoresis and immunoblotting.
SDS-slab gel electrophoresis was performed on 3-30% PAGE (280 X 140 X 0.75 mm) according to Laemmli (30) . The gels were run at 200 V (constant voltage) for 20 h. Some gels were stained with Coomassie Brilliant Blue R-250 and dried. From other gels, the proteins were transferred electrophoretically to nitrocellulose filters (Schleider and Schultz, Darsel, FRG) essentially as described by Towbin et al. (31) . The nitrocellulose paper was washed with a buffer containing 10 mM Tris-HCI, 150 mM NaCl, 3% BSA, and 0.2% Tween 20, pH 7.4, and was then incubated overnight with the different MAbs diluted 1:1,000 in the same buffer. After the filters were washed, they were incubated with peroxidase-labeled rabbit anti-mouse IgG (Nordic Immunology, Tilburg, The Netherlands) 1:1,000 dilution in washing buffer. The proteins were visualized with diamino-benzidine-tetrahydrochloride (0.5 g/liter in 50 mm Tris-HCl buffer, pH 7.6, containing 0.006% H202). Table I) .
We now have screened a panel of MAbs for their ability to inhibit the binding of von Willebrand factor to extracellular matrices of cultured endothelial cells and smooth muscle cells. As shown in Table I , CLB-RAg 201 has no significant influence on the binding of von Willebrand factor to the matrices. However, another MAb, CLB-RAg 38, inhibited the binding of von Willebrand factor to both types of matrix to the same extent as an excess amount of unlabeled von Willebrand factor did (Table I) . Using purified IgG, 4.8 .g/ml CLB-RAg 38 completely inhibits the binding of 125I-von Willebrand factor to endothelial cell matrices, while up to 200 ,g/ml CLB-RAg 201 had no significant effect on it. CLB-RAg 35, an MAb that inhibits the interaction between von Willebrand factor and platelets, had no influence on the binding of von Willebrand factor to the matrices.
The effect of CLB-RAg 201 and CLB-RAg 38 on the binding of von Willebrand factor to endothelial cell matrices was also tested in the perfusion system. Perfusions were performed with 2 ,g/ml '25I-von Willebrand factor added to a 4% HAS. A mean value of 11.4 ng 125I-von Willebrand factor bound/cm2 of the coverslips. In the presence of CLB-RAg 38, 6.0 ng 125-von Willebrand factor was bound/cm2; no inhibition was found in the presence of CLB-RAg 201.
In another series of experiments, the binding of '251-von Willebrand factor to the subendothelium of human umbilical arteries was studied (Table I) . A rapid binding of von Willebrand factor was found. This binding however, could not be inhibited by a 20-fold excess of unlabeled von Willebrand factor. This indicates that the binding of von Willebrand factor to the denuded arteries in this concentration range is not saturable (see also reference 6). This may be the reason that no inhibition occurred with any of the MAbs. Binding ofvon Willebrandfactor to purified collagens. The inhibition ofbinding of von Willebrand factor by CLB-RAg 38 was studied in more detail (Table II) . Various types ofcollagen and fibronectin were coated onto microtiter wells and then incubated with plasma. von Willebrand factor bound strongly to fibrillar collagen type I and to fibrillar and monomeric collagen type III. This binding was inhibited by CLB-RAg 201 but not by CLB-RAg 38. When using purified IgG, 1 ,ug/ml CLBRAg 201 completely inhibits the binding while 480 gg/ml CLB-RAg 38 has no effect at all on the binding of von Willebrand factor to collagen type III. von Willebrand factor did not bind to monomeric collagen types I, IV, V, VI, or to fibronectin. This absence of interaction was not due to the lack of binding of the latter collagens and fibronectin to plastic since their presence was readily demonstrated by an ELISA using the appropriate specific antisera (data not shown). When purified von Willebrand factor was used instead ofplasma, comparable results were obtained, except that purified von Willebrand factor also bound to collagen type V (not shown). This binding could not be inhibited by both CLIA-RAg 201 and CLB-RAg 38. When Fab fragments obtained from CLB-RAg 201 and CLB-RAg 38 were used to study the inhibition of von Willebrand factor to fibrillar collagen type I, the same results were obtained as with the MAbs themselves.
Platelet adhesion to extracellular matrices. In order to investigate the role of the different domains on von Willebrand factor in the interaction of platelets with the extracellular matrices of endothelial cells and smooth muscle cells, and with subendothelium, perfusions were performed with whole blood preincubated with the different MAbs (Table III) . Platelet adhesion to the matrix of endothelial cells and to subendothelium was completely inhibited by CLB-RAg 35. Previously, (17) it has been shown that this antibody completely inhibited both the binding of von Willebrand factor to platelets in the presence of ristocetin and the adhesion of platelets to subendothelium. Preincubation of plasma with 48 ,ug/ml CLB-RAg 38 or with 40 ,ug/ml CLB-RAg 201 partly inhibited the adhesion of platelets to endothelial cell matrices and subendothelium. The adhesion of platelets to smooth muscle cell matrices was inhibited for -75% by CLB-RAg 38 and CLB-RAg 35, while CLB-RAg 201 inhibited platelet adhesion to these matrices for -45%. WB + CLB-RAg 3S 5±2 (n = 11) 24 (n = 2) 6±2 (n =7) WB + CLB-RAg 201 59±3 (n = 10) 55 (n = 2) 59±12 (n = 8) WB + CLB-RAg 38 57±7 (n = 4) 28 (n = 2) 55±9 (n = 5)
Endothelial cell (EC) and smooth muscle cell (SMC) matrices were perfused with whole blood for 5 min at a shear rate of 1,300 s-'. Subendothelium was perfused for 5 min at a shear rate of 1,800 s-' with a perfusate that consisted of washed red blood cells (40% hematocrit), normal citrated plasma, and "'In-labeled blood platelets (final concentration 205 X 103/,A). MAbs were added to the plasma 5 min before the perfusion. After perftision the matrices were fixed and stained, and the surface coverage by platelets was determined by morphometric evaluation. The number of platelets adhering to subendothelium was calculated from the specific radioactivity and the radioactivity on the surface after perfusion. Results are expressed as % of adherence to matrices or to subendothelium preincubated with control ascites (mean±SD). WB, whole blood.
presence or absence of MAbs (Table IV) (Table V) . First perfusions were carried out with plasma alone or with plasma with added MAbs. Then a second perfusion was carried out with "'In-labeled platelets (190,000/Ml) and red blood cells (hematocrit, 40%) resuspended in HAS, with or without MAbs. When subendothelium was perfused first with plasma, to which CLB-RAg 38 or CLB-RAg 201 was added, and subsequently with In-labeled platelets, an inhibition comparable with the results shown in Table III occurred. However, when the subendothelium was first perfused with plasma (containing von Willebrand factor), and then with platelets and MAbs (in the absence of von Willebrand factor), CLB-RAg 201 still inhibited the platelet adhesion while CLB-RAg 38 had no inhibitory effect anymore. These results indicate that CLB-RAg 201 inhibited the functional activity of the von Willebrand factor (Fig. 1) . In order to characterize the domains recognized by the MAbs present on the fragments, the peak fractions were pooled, applied to gel electrophoresis, and immunoblotted. Although the main fragment present in pool 2 was a 20-kD peptide shown with Coomassie staining, after blotting CLB-RAg 201, it recognized a fragment with a molecular weight of 48,000 in this pool. Another fragment with a molecular weight of 82,000 present in pool 4 was recognized by CLB-RAg 38. This fragment was also recognized by CLB-RAg 41. This MAb has previously been used for the recognition of von Willebrand factor-specific cDNA in an endothelial cell cDNA library. Its epitope appeared to reside on the 37,000 D carboxy-terminal fragment of the molecule (35) . gested for 24 h with L(tosylamido 2-phenyl)ethylchloromethylketone-FPLC treated trypsin. The digest was applied to FPLC Mono Q-ionexchange chromatography; the tryptic fragments were eluted with a linear gradient of NaCi (0-0.5 M), and fractions were collected (a). Based on the absorbance at 280 nM, the fractions were pooled as indicated and applied to a 3-30% PAGE. After electrophoresis, gels were stained with Coomassie Brilliant Blue R-250 (CB) or the proteins were electrophoretically transferred to nitrocellulose filter. After washing the filters, they were incubated with 1:100 dilution of CLB-RAg 201 (b) or CLB-RAg 38 (c). The MAbs were detected by incubation with peroxidase-labeled rabbit anti-mouse, followed by incubation with benzidine-tetrahydrochloride (0.5 g/liter in 50 nM Tris (Tables IV and V) . No inhibition could be found when von Willebrand factor was already bound to the subendothelium before the antibodies were added (Table V) . CLB-RAg 201, the MAb directed to the epitope present on the von Willebrand factor molecule involved in the interaction In bleeding time skin wounds, perivascular collagen fibers become exposed and von Willebrand factor might mediate platelet adhesion to these fibers. There may be a difference between von Willebrand binding in a thrombotic situation (minimal damage, binding to subendothelium) and in a hemostatic situation (breach in vessel, perivascular fibrillar collagen exposed). Nevertheless, we conclude that both in subendothelium and in the extracellular matrices the major binding site for von Willebrand factor is not collagen.
There is an interesting difference in inhibition between platelet adherence to the endothelial cell matrix and to the smooth muscle cell matrix. CLB-RAg 35, the antibody that blocks the binding of von Willebrand factor to GPIb, inhibits 95% of the adhesion to endothelial cell matrices while only 75% of the adhesion to smooth muscle cell matrices is inhibited. Possible explanations for this inconsistency are (a) that on smooth muscle cell matrices another type ofinteraction ofvon Willebrand factor with platelets is induced (GPIIbIIIa) or (b) that a part of the platelet adhesion to these matrices at the shear rate that was used is independent of von Willebrand factor.
von Willebrand factor binds strongly to collagen types I and III compared with other purified matrix proteins. When purified collagen types I and III are spread on glass coverslips and then exposed to flowing blood, platelets will rapidly adhere (29) . The extracellular matrix ofcultural human endothelial cells and smooth muscle cells contains a substantial amount of collagen type III (36, 37 (39) . The nature of this substance is unknown. Further studies are needed to clarify this important aspect of the adhesion of platelets to damaged vessels.
On the basis of the results presented in this paper and on the basis of previous fluorescence studies (8, 15, 16) , it can be concluded that collagen is not the primary binding site of von Willebrand factor in the vessel wall in the described system.
